Global Literature Review
Maintain compliance and enhance safety oversight with expert-driven literature evaluation and reporting.
Literature Search
The review of worldwide scientific literature is an essential part of the ongoing safety surveillance of medicinal products, regardless of commercial status. To ensure compliance with regulatory legislation worldwide, it is essential that global and local literature screening, where applicable, is regularly conducted to identify reportable ICSRs and safety relevant information.
Our experienced team at ProPharma can support you or assume full responsibility for these activities to ensure your PV program adheres to the global regulatory requirements.
In addition, our services are cost-effective, and we are able to conduct global literature surveillance of large bibliographical databases including Medline® via the Biologit platform.
We have extensive experience in developing robust search strategies for our clients and providing results from these searches according to an agreed upon periodicity. We can perform the review and assessment of identified literature articles and ensure the efficient and auditable documentation of results.
We have experience and well-established processes for conducting local literature screenings. We can support you in the set-up and conduct, including the identification of relevant local databases and journals, and translation of articles, if needed.
For Marketing Authorization Holders (MAHs) with active substances included in the EMA’s Medical Literature Monitoring (MLM) list, we perform EudraVigilance checks using the ICSR Export module based on the frequency contracted. In addition, we provide local literature searches in relevant local scientific and medical journals in countries where your product is marketed and where this is legally required.
News & Insights
June 15, 2026
Five Metrics That Predict CRO Success (and How to Measure Them)
Discover five key metrics to evaluate CRO success, ensuring timely clinical trials and data integrity while minimizing costs. Learn how to measure them effectively.
June 10, 2026
FDA Adds Bemotrizinol to OTC Sunscreen Monograph: What the New GRASE Determinati...
Learn how bemotrizinol achieved GRASE status and what FDA's final order adding the ingredient to the OTC sunscreen monograph means for manufacturers and product development.
June 18, 2026
ProPharma Welcomes Kevin van Dooren to Strengthen Integrated EU Regulatory and H...
ProPharma welcomes Kevin van Dooren as Vice President, HEOR and Market Access, strengthening integrated EU regulatory, HTA, reimbursement, and market access capabilities for life sciences companies.
May 27, 2026
ProPharma Appoints Adrian Pencak as Chief Commercial Officer
ProPharma announces Adrian Pencak as Chief Commercial Officer, bringing 25 years of leadership experience to enhance global commercial capabilities and client partnerships.
January 31, 2025
ProPharma Recognized for AI Excellence at ECCCSA
ProPharma wins Silver at ECCCSA for AI innovation in Medical Information, enhancing efficiency and quality in delivering accurate medical information.
October 9, 2024
ProPharma Receives 2024 CPHI Regulatory and Compliance Award
ProPharma wins CPHI Pharma Award for excellence in regulatory and compliance innovation, enhancing efficiency and accelerating market access for life-saving therapies.
June 17, 2026
Meeting Patients Where They Are: Delivering Global Clinical Support for Time-Sen...
Conducting clinical research for rare pediatric populations presents unique operational challenges, particularly when eligible patients may be born anywhere in the world and require immediate...
June 10, 2026
Accelerating Commercial Readiness for a Novel Cell Therapy Program
As advanced therapy developers move from research-stage operations toward commercialization, they often face significant challenges in scaling quality systems, aligning regulatory strategy, and...
June 2, 2026
Foundations of a Compliant EU–UK GMP–GDP Supply Chain: From Importation to Distribution
A compliant and efficient EU–UK GMP–GDP supply chain requires a clear understanding of roles, responsibilities, and operational integration across importation, certification, and distribution...
April 23, 2026
Clinical Promise to Commercial Reality: The Path to Cell & Gene Therapy Market
As cell and gene therapies transition from clinical development to commercialization, organizations face evolving regulatory expectations, expanded CMC requirements, and increased MAH...
April 9, 2026
EMA Policy 0070: Advanced Strategies for Compliance, Anonymization, and CCI Justification
As European Medicines Agency Policy 0070 enters its expanded Step 2 phase, sponsors face increased document volumes, heightened transparency obligations, and greater scrutiny of anonymization and CCI...
News & Insights
June 17, 2026
Meeting Patients Where They Are: Delivering Global Clinical Support for Time-Sen...
Conducting clinical research for rare pediatric populations presents unique operational challenges, particularly when eligible patients may be born anywhere in the world and require immediate...
April 9, 2026
EMA Policy 0070: Advanced Strategies for Compliance, Anonymization, and CCI Justification
As European Medicines Agency Policy 0070 enters its expanded Step 2 phase, sponsors face increased document volumes, heightened transparency obligations, and greater scrutiny of anonymization and CCI...